INmune Bio Executes Warrant Inducement and Extension Agreement
I'm LongbridgeAI, I can summarize articles.Inmune Bio executed a warrant inducement agreement on June 30, 2026. Investors exercised 50% of their April 2024 warrants at a reduced price of $1.40 per share, generating approximately $905,957 in proceeds. In exchange, the maturity for the remaining warrants was extended to December 31, 2027. The company aims to maintain equity capital access while offering improved terms.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Inmune Bio ( (INMB) ) has provided an announcement.
On June 30, 2026, INmune Bio entered into a warrant inducement agreement and a second amendment with certain holders of common stock purchase warrants issued in April 2024. The company offered these investors the chance to exercise 50% of their warrants at a reduced price of $1.40 per share, down from $1.95, in return for extending the remaining warrants’ maturity from June 30, 2026, to December 31, 2027.
Under the inducement, holders agreed to exercise 647,112 warrants for cash, purchasing an equal number of common shares and providing INmune Bio with approximately $905,957 in proceeds. The remaining 50% of the April 2024 warrants now carry the extended maturity, and the underlying shares are covered by an effective registration statement, ensuring the company maintains access to equity capital while offering investors improved warrant terms.
The most recent analyst rating on (INMB) stock is a Buy
with a $8.00 price target.
To see the full list of analyst forecasts on Inmune Bio stock,
see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
INMB’s score is held back primarily by weak financial performance (pre-commercial revenue profile, persistent losses, and ongoing cash burn with limited runway). Offsetting this are constructive technicals (price above major moving averages with neutral-positive momentum) and generally positive execution/regulatory milestones from the earnings call and recent corporate updates, though financing and development/timeline risks remain meaningful.
To see Spark’s full report on INMB stock,
click here.
More about Inmune Bio
INmune Bio Inc., a biotechnology company, focuses on developing immunotherapies that harness the innate immune system to treat serious diseases. The company operates in the biopharmaceutical sector, funding its research and clinical programs through equity offerings and related securities such as common stock purchase warrants.
Average Trading Volume: 624,837
Technical Sentiment Signal: Sell
Current Market Cap: $43.33M